Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

HSP60 predicts survival in advanced serous ovarian cancer.

Hjerpe E, Egyhazi S, Carlson J, Stolt MF, Schedvins K, Johansson H, Shoshan M, Avall-Lundqvist E.

Int J Gynecol Cancer. 2013 Mar;23(3):448-55. doi: 10.1097/IGC.0b013e318284308b.

PMID:
23429486
2.

High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanoma.

Jonsson A, Tuominen R, Grafström E, Hansson J, Egyhazi S.

J Invest Dermatol. 2010 Dec;130(12):2809-17. doi: 10.1038/jid.2010.216. Epub 2010 Aug 12.

3.

MicroRNA expression profiles associated with mutational status and survival in malignant melanoma.

Caramuta S, Egyházi S, Rodolfo M, Witten D, Hansson J, Larsson C, Lui WO.

J Invest Dermatol. 2010 Aug;130(8):2062-70. doi: 10.1038/jid.2010.63. Epub 2010 Apr 1.

4.

Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations.

Jovanovic B, Egyhazi S, Eskandarpour M, Ghiorzo P, Palmer JM, Bianchi Scarrà G, Hayward NK, Hansson J.

J Invest Dermatol. 2010 Feb;130(2):618-20. doi: 10.1038/jid.2009.287. Epub 2009 Sep 17. No abstract available.

5.

Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.

Platz A, Egyhazi S, Ringborg U, Hansson J.

Mol Oncol. 2008 Apr;1(4):395-405. doi: 10.1016/j.molonc.2007.12.003. Epub 2007 Dec 28.

6.

MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parameters.

Höiom V, Tuominen R, Käller M, Lindén D, Ahmadian A, Månsson-Brahme E, Egyhazi S, Sjöberg K, Lundeberg J, Hansson J.

Pigment Cell Melanoma Res. 2009 Apr;22(2):196-204. doi: 10.1111/j.1755-148X.2008.00526.x. Epub 2008 Dec 9.

PMID:
19077144
7.

Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.

Baselga J, Zambetti M, Llombart-Cussac A, Manikhas G, Kubista E, Steger GG, Makhson A, Tjulandin S, Ludwig H, Verrill M, Ciruelos E, Egyhazi S, Xu LA, Zerba KE, Lee H, Clark E, Galbraith S.

J Clin Oncol. 2009 Feb 1;27(4):526-34. doi: 10.1200/JCO.2007.14.2646. Epub 2008 Dec 15.

PMID:
19075286
8.

Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma.

Johansson CC, Egyházi S, Masucci G, Harlin H, Mougiakakos D, Poschke I, Nilsson B, Garberg L, Tuominen R, Linden D, Stolt MF, Hansson J, Kiessling R.

Cancer Immunol Immunother. 2009 Jul;58(7):1085-94. doi: 10.1007/s00262-008-0631-1. Epub 2008 Nov 28.

PMID:
19039588
9.

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.

Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, Hansson J, Wu H, King AJ, Van Belle P, Elder DE, Flaherty KT, Herlyn M, Nathanson KL.

Mol Cancer Ther. 2008 Sep;7(9):2876-83. doi: 10.1158/1535-7163.MCT-08-0431.

10.

Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma.

Jovanovic B, Kröckel D, Linden D, Nilsson B, Egyhazi S, Hansson J.

J Invest Dermatol. 2008 Nov;128(11):2696-704. doi: 10.1038/jid.2008.134. Epub 2008 May 29.

11.

FBXW7/hCDC4 is a general tumor suppressor in human cancer.

Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D, Marth C, Mueller-Holzner E, Corcoran M, Dagnell M, Nejad SZ, Nayer BN, Zali MR, Hansson J, Egyhazi S, Petersson F, Sangfelt P, Nordgren H, Grander D, Reed SI, Widschwendter M, Sangfelt O, Spruck C.

Cancer Res. 2007 Oct 1;67(19):9006-12. Erratum in: Cancer Res. 2008 Feb 15;68(4):1245. Dofou, Dimitra [corrected to Dafou, Dimitra].

12.

NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.

Edlundh-Rose E, Egyházi S, Omholt K, Månsson-Brahme E, Platz A, Hansson J, Lundeberg J.

Melanoma Res. 2006 Dec;16(6):471-8.

PMID:
17119447
13.

Detection of MC1R polymorphisms with protease-mediated allele-specific extension as an alternative to direct sequencing.

Käller M, Tuominen R, Ahmadian A, Magnusson V, Egyhazi S, Hansson J, Lundeberg J.

Clin Chem. 2005 Dec;51(12):2388-91. No abstract available.

14.

Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.

Pawitan Y, Bjöhle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, Liu ET, Miller L, Nordgren H, Ploner A, Sandelin K, Shaw PM, Smeds J, Skoog L, Wedrén S, Bergh J.

Breast Cancer Res. 2005;7(6):R953-64. Epub 2005 Oct 3.

15.

Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival.

Grafström E, Egyházi S, Ringborg U, Hansson J, Platz A.

Clin Cancer Res. 2005 Apr 15;11(8):2991-7.

16.

Proteinase K added to the extraction procedure markedly increases RNA yield from primary breast tumors for use in microarray studies.

Egyházi S, Bjöhle J, Skoog L, Huang F, Borg AL, Frostvik Stolt M, Hägerström T, Ringborg U, Bergh J.

Clin Chem. 2004 May;50(5):975-6. No abstract available.

17.

O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma.

Ma S, Egyházi S, Ueno T, Lindholm C, Kreklau EL, Stierner U, Ringborg U, Hansson J.

Br J Cancer. 2003 Oct 20;89(8):1517-23.

18.

Novel O6-methylguanine-DNA methyltransferase SNPs: a frequency comparison of patients with familial melanoma and healthy individuals in Sweden.

Egyházi S, Ma S, Smoczynski K, Hansson J, Platz A, Ringborg U.

Hum Mutat. 2002 Nov;20(5):408-9.

PMID:
12402349
19.

Analysis of O(6)-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy.

Ma S, Egyházi S, Martenhed G, Ringborg U, Hansson J.

Melanoma Res. 2002 Aug;12(4):335-42.

PMID:
12170182
21.
22.
23.

Immunohistochemical examination of the expression of O6-methylguanine-DNA methyltransferase in human melanoma metastases.

Egyházi S, Margison GP, Hansson J, Ringborg U.

Eur J Cancer. 1997 Jan;33(1):129-34. Erratum in: Eur J Cancer 1997 Apr;33(4):701.

PMID:
9071912
24.
25.

Increased cisplatin sensitivity of human fibroblasts from a subject with inherent glutathione deficiency.

Hansson J, Edgren MR, Egyházi S, Hao XY, Mannervik B, Ringborg U.

Acta Oncol. 1996;35(6):683-90.

PMID:
8938214
26.

Apoptosis and c-jun induction by cisplatin in a human melanoma cell line and a drug-resistant daughter cell line.

Zhao R, Rabo YB, Egyházi S, Andersson A, Edgren MR, Linder S, Hansson J.

Anticancer Drugs. 1995 Oct;6(5):657-68.

PMID:
8845476
27.

O6-methylguanine-DNA methyltransferase activities in biopsies of human melanoma tumours.

Egyházi S, Hansson J, Ringborg U.

Br J Cancer. 1995 Jan;71(1):37-9.

28.

Contribution of glutathione transferase M3-3 to 1,3-bis(2-chloroethyl)-1-nitrosourea resistance in a human non-small cell lung cancer cell line.

Berhane K, Hao XY, Egyházi S, Hansson J, Ringborg U, Mannervik B.

Cancer Res. 1993 Sep 15;53(18):4257-61.

29.

Carmustine-induced toxicity, DNA crosslinking and O6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines.

Egyházi S, Bergh J, Hansson J, Karran P, Ringborg U.

Eur J Cancer. 1991;27(12):1658-62.

PMID:
1664221

Supplemental Content

Loading ...
Support Center